Summary
- Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO.
- The firm is advancing treatments for various muscle diseases.
- DYN has yet to enter Phase 1 safety trials, so the IPO may be more relevant for long-term hold institutional investors.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Dyne Therapeutics (DYN) intends to raise $175 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is a pre-clinical stage developer of treatment candidates for various serious muscle diseases.
Dyne hasn’t entered Phase 1 safety trials yet, so the stock is ultra-high-risk and may be more suited to institutional investors with a long-term hold time frame.
Company & Technology
Waltham, Massachusetts-based Dyne was founded to develop treatments for muscle diseases such as Myotonic dystrophy, Duchenne muscular dystrophy and Faciocapulohumeral muscular dystrophy.
Management is headed by president and Chief Executive Officer Mr. Joshua Brumm, who has been with the firm since October 2019 and was previously COO and CFO at Kaleido Biosciences and the same at Versartis, both biopharma firms.
Below is a brief overview video of myotonic dystrophy:
